Curative Biosciences Inc
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. It intends to manufacture and market natural health products and operate in the medical cannabis industry. The company was formerly known as Amaize Beverage Corporation and changed its name to Curative Biosciences, Inc. in August 2017. Curative Biosciences, Inc. was founded in 2009 an… Read more
Curative Biosciences Inc (CBDX) - Total Liabilities
Latest total liabilities as of March 2018: $719.54K USD
Based on the latest financial reports, Curative Biosciences Inc (CBDX) has total liabilities worth $719.54K USD as of March 2018.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Curative Biosciences Inc - Total Liabilities Trend (2014–2017)
This chart illustrates how Curative Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Curative Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Curative Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
American Films Inc
PINK:AMFL
|
USA | $3.00 Million |
|
Yuexiu Real Estate Investment Trust
F:D3N
|
Germany | €42.64 Billion |
|
BURCON NUTRASCIENCE
MU:BNE
|
Germany | €5.96 Million |
|
Cizzle Biotechnology Holdings PLC
LSE:CIZ
|
UK | GBX533.00K |
|
Anchor Land Holdings Inc
PSE:ALHI
|
Philippines | ₱28.10 Billion |
|
Sakana SA
WAR:SKN
|
Poland | zł3.60 Million |
Liability Composition Analysis (2014–2017)
This chart breaks down Curative Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 51.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curative Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curative Biosciences Inc (2014–2017)
The table below shows the annual total liabilities of Curative Biosciences Inc from 2014 to 2017.
| Year | Total Liabilities | Change |
|---|---|---|
| 2017-06-30 | $633.07K | +2.07% |
| 2016-06-30 | $620.22K | -12.12% |
| 2015-06-30 | $705.76K | +85.02% |
| 2014-06-30 | $381.44K | -- |